Scarica l'app Stockscreener
54.28
1.51%
-0.83
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$55.11
Aprire:
$55.3
Volume 24 ore:
645.80K
Relative Volume:
0.66
Capitalizzazione di mercato:
$1.10B
Reddito:
$90.12M
Utile/perdita netta:
$-276.06M
Rapporto P/E:
-37.18
EPS:
-1.46
Flusso di cassa netto:
$-193.47M
1 W Prestazione:
-4.23%
1M Prestazione:
-8.59%
6M Prestazione:
+8,482%
1 anno Prestazione:
+5,274%
Intervallo 1D:
$53.29
$56.50
Intervallo di 1 settimana:
$53.29
$61.80
Portata 52W:
$0.432
$66.92
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Confronta NKTR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
54.28 | 1.12B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Nektar Therapeutics announces chief legal officer transition effective year-end By Investing.com - Investing.com India
Nektar Therapeutics Announces Chief Legal Officer Departure - TipRanks
Nektar Therapeutics announces chief legal officer transition effective year-end - Investing.com
Nektar Therapeutics Announces Chief Legal Officer Change - TradingView
Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma - HCPLive
Can Nektar Therapeutics (ITH0) stock stage a strong rebound this quarterMarket Risk Summary & Daily Market Momentum Tracking - newser.com
Will Nektar Therapeutics (ITH0) stock beat Nasdaq index returns2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com
Nektar at Jefferies: Biologics in Focus for New Indications By Investing.com - Investing.com Australia
Nektar at Jefferies: Biologics in Focus for New Indications - Investing.com
Nektar Therapeutics (NKTR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How big funds are accumulating Nektar Therapeutics (ITH0) stockMarket Rally & Long-Term Safe Investment Ideas - newser.com
Will Nektar Therapeutics (ITH0) stock profit from fiscal stimulusWeekly Risk Summary & AI Optimized Trading Strategy Guides - newser.com
Is Nektar Therapeutics stock attractive for passive investorsJuly 2025 EndofMonth & AI Powered Trade Plan Recommendations - newser.com
How Nektar Therapeutics (ITH0) stock trades in high volatilityMarket Risk Analysis & Safe Entry Zone Tips - newser.com
What RSI levels show for Nektar Therapeutics (ITH0) stock2025 Major Catalysts & Capital Efficiency Focused Strategies - newser.com
Is it time to cut losses on Nektar TherapeuticsJuly 2025 Highlights & Verified Entry Point Signals - newser.com
Will Nektar Therapeutics stock benefit from AI adoptionJuly 2025 Outlook & Daily Entry Point Alerts - newser.com
How Recent Clinical Wins and Risks Are Changing the Story for Nektar Therapeutics - Yahoo Finance
Using economic indicators to assess Nektar Therapeutics potential2025 Institutional Moves & Weekly Watchlist for Consistent Profits - newser.com
Can volume confirm reversal in Nektar Therapeutics2025 EndofYear Setup & Growth Focused Stock Reports - newser.com
How geopolitical risks impact Nektar Therapeutics (ITH0) stock2025 EndofYear Setup & Intraday High Probability Alerts - newser.com
What technical charts say about Nektar Therapeutics stockJuly 2025 Opening Moves & Real-Time Market Sentiment Alerts - newser.com
Why Nektar Therapeutics (ITH0) stock is a must watch ticker2025 Top Decliners & Technical Buy Zone Confirmations - newser.com
Why Nektar Therapeutics stock remains on buy listsTrade Volume Report & Low Risk High Reward Ideas - newser.com
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):